Pharmaceutical firm G1 Therapeutics scored USD 12.5 million from MedImmune Ventures and other investors in its Series A funding round.
Investors
Naivas ends talks with Wal-Mart
Kenyan retailer Naivas said that it had ended its talks with Massmart, a Wal-Mart Stores Inc. subsidiary in East Africa.
Edgewood Partners explores sale- sources
People familiar with the matter told Bloomberg that Edgewood Partners was looking for bidders for the insurance firm.
Imperial Capital Group invests USD 17 million in STI Technologies
Imperial Capital Group backed STI Technologies with a USD 17 million investment. Toronto-based Imperial Capital Group announced its USD 17 million investment in reimbursement card provider STI Technologies.
Veeva shares increase 83% post-IPO, raises USD194 million
According to a Techcrunch report, the initial public offering of enterprise cloud provider Veeva Systems saw its shares climbed almost 84% and had raised USD194 million.
Latest News
Texas-based private equity firm Cotton Creek Capital bought Royal Baths Manufacturing for an undisclosed amount.
PPF Group, a Czech investment group, had discussed with Telefonica regarding a possible acquisition deal for the Spanish telecoms' unit in Czech Republic.
The China Securities Regulatory Commission approved the application of China Everbright Bank Co to hold a share sale overseas and raise USD 2 billion.
Biopharmaceutical firm SAGE Therapeutics scored USD 20 million from ARCH Venture Partners and Third Rock Ventures in its Series B funding round.
Vivendi, a French mass media company, said it would acquire USD2.7 billion of its U.S. dollar-denominated debt after it received payment for its stake sale in Activision Blizzard.
South Korean communication app maker Line would stand to be valued at USD8 billion should it go public, according to information technology news site The Next Web.
A Wall Street Journal report might have indicated that Apple Inc had sold more iPhone 5S units than the cheaper iPhone 5C units.
Monte dei Paschi foundation had been in discussions with the Italian Treasury regarding a stake sale deal, said sources in a Reuters report.
The therapeutic protein molecule Anticalin would be the subject of the an agreement between Zydus and Pieris.
